"Uterine Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the UTERUS.
| Descriptor ID |
D014594
|
| MeSH Number(s) |
C04.588.945.418.948 C13.351.500.852.762 C13.351.937.418.875
|
| Concept/Terms |
Uterine Neoplasms- Uterine Neoplasms
- Neoplasms, Uterus
- Neoplasm, Uterus
- Uterus Neoplasm
- Uterus Neoplasms
- Neoplasms, Uterine
- Neoplasm, Uterine
- Uterine Neoplasm
Cancer of Uterus- Cancer of Uterus
- Uterus Cancers
- Cancer of the Uterus
- Uterus Cancer
- Cancer, Uterus
- Cancers, Uterus
- Uterine Cancer
- Cancer, Uterine
- Cancers, Uterine
- Uterine Cancers
|
Below are MeSH descriptors whose meaning is more general than "Uterine Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Uterine Neoplasms".
This graph shows the total number of publications written about "Uterine Neoplasms" by people in this website by year, and whether "Uterine Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 4 | 0 | 4 |
| 2006 | 7 | 0 | 7 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 1 | 5 |
| 2013 | 6 | 1 | 7 |
| 2014 | 6 | 0 | 6 |
| 2015 | 9 | 0 | 9 |
| 2016 | 9 | 4 | 13 |
| 2017 | 10 | 2 | 12 |
| 2018 | 13 | 1 | 14 |
| 2019 | 4 | 0 | 4 |
| 2020 | 15 | 0 | 15 |
| 2021 | 12 | 0 | 12 |
| 2022 | 17 | 0 | 17 |
| 2023 | 20 | 0 | 20 |
| 2024 | 17 | 2 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uterine Neoplasms" by people in Profiles.
-
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
-
Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 Dec; 78:103411.
-
Associations Between Earlier Menarche and Fibroid Severity in Individuals Seeking Hysterectomy. J Womens Health (Larchmt). 2025 Jan; 34(2):235-241.
-
Geographic and racial disparities in the quality of surgical care among patients with nonmetastatic uterine cancer. Am J Obstet Gynecol. 2025 Mar; 232(3):308.e1-308.e15.
-
Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells. 2024 08 28; 13(17).
-
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 Aug; 28(8):669-687.
-
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
-
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
-
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells. 2024 06 26; 13(13).
-
Targeting Bromodomain-Containing Protein 9 in Human Uterine Fibroid Cells. Reprod Sci. 2025 Jan; 32(1):103-115.